Adaptive Biotechnologies Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 0/6
Adaptive Biotechnologies şirketinin temettü ödeme geçmişi bulunmamaktadır.
Anahtar bilgiler
n/a
Temettü verimi
-1.6%
Geri Alım Getirisi
| Toplam Hissedar Getirisi | -1.6% |
| Gelecekteki Temettü Verimi | 0% |
| Temettü Büyümesi | n/a |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | n/a |
| Ödeme oranı | n/a |
Son temettü ve geri alım güncellemeleri
Güncelleme yok
Recent updates
Anlatı Güncellemesi • May 17
ADPT: 2026 MRD Execution And Margin Discipline Will Support Future Upside Potential
Analysts now see Adaptive Biotechnologies' fair value edging from $20.57 to $20.14, reflecting mixed price target revisions. One firm cut its target by $3, while another raised its target by $2, as they update assumptions around growth, margins, the discount rate and future P/E expectations.Anlatı Güncellemesi • May 01
ADPT: 2026 MRD Outlook And Margin Discipline Will Drive Future Upside Potential
The updated analyst price target for Adaptive Biotechnologies moves slightly lower to about $20.57 from $20.86. Analysts attribute this change to modest adjustments to fair value estimates, discount rate assumptions, and longer term profit margin and P/E expectations.
Anlatı Güncellemesi • Apr 16
ADPT: MRD Revenue Outlook And Refreshed Models Will Support Future Cash Flows
Narrative Update on Adaptive Biotechnologies The consensus analyst price target for Adaptive Biotechnologies has moved up by $1, reflecting updated analyst models that incorporate adjusted discount rates, refreshed revenue growth and profit margin assumptions, and a revised, still very large forward P/E framework. Analyst Commentary Recent Street research on Adaptive Biotechnologies centers on modestly higher price targets, with several bullish analysts revising their models at roughly the same time.Anlatı Güncellemesi • Apr 02
ADPT: MRD 2026 Outlook And Discount Assumptions Will Support Future Upside Potential
Analysts have raised their price targets on Adaptive Biotechnologies by about $1, reflecting updated views on discount rates, growth, margins, and future P/E assumptions. These changes keep the stock's fair value estimate effectively unchanged at around $21.Anlatı Güncellemesi • Mar 19
ADPT: MRD Outlook And Pfizer Agreements Will Support Future Cash Flows
Analysts have inched their average price targets on Adaptive Biotechnologies higher, often by about $1 increments. These changes reflect updated views that modestly adjust revenue growth, profit margin and future P/E assumptions while keeping the fair value estimate near $22.Anlatı Güncellemesi • Mar 04
ADPT: MRD And Pfizer Agreements Will Support Future Cash Flow Upside
The analyst price target for Adaptive Biotechnologies has shifted from $21.00 to $22.00. Analysts point to updated assumptions around growth, profitability, and long-term P/E expectations following a series of recent target increases across the Street.Anlatı Güncellemesi • Feb 18
ADPT: Pfizer Agreements And MRD Progress Will Support Future Upside Potential
Analysts have nudged their average price target for Adaptive Biotechnologies higher by about $1, reflecting updated fair value assumptions and slightly revised views on growth, margins and future P/E, in line with recent target increases from several research firms. Analyst Commentary Recent research updates cluster around modest target increases and a generally supportive view of Adaptive Biotechnologies, with most of the focus on refreshed fair value work rather than sweeping changes to the thesis.Anlatı Güncellemesi • Feb 03
ADPT: Sector Tailwinds And Pfizer Partnerships Will Support Measured Future Upside
Analysts have nudged their price targets on Adaptive Biotechnologies slightly higher, with Street research pointing to target increases such as TD Cowen moving to $20 from $19. This contributes to a modest lift in our fair value estimate from $20.00 to about $20.14 as they highlight solid expected sector results and fundamentals.Anlatı Güncellemesi • Jan 20
ADPT: Sector Tailwinds And Cancer Testing Leadership Will Support Future Upside
Narrative Update: Adaptive Biotechnologies The analyst price target for Adaptive Biotechnologies has moved from $19 to $20, reflecting updated views that incorporate recent Q4 preview work on diagnostics peers, expectations for solid sector results and 2026 outlooks, and the company’s latest Q3 report. Analyst Commentary Recent Street research around Adaptive Biotechnologies has focused on updated price targets that reflect fresh sector work and the company’s latest Q3 report.Anlatı Güncellemesi • Jan 05
ADPT: MRD Platform And Pfizer Agreements Will Support Long-Term Cash Flow Upside
Analysts have lifted their price target on Adaptive Biotechnologies to $16 from $11, citing the recent Q3 report as the key driver behind this updated view. Analyst Commentary Bullish Takeaways Bullish analysts point to the new US$16 price target, up from US$11, as a sign that expectations for execution and risk reward have shifted in a more constructive direction after the recent Q3 report.Seeking Alpha • Dec 26
Adaptive Biotechnologies: 2026 Is The Durability Test, Not The Hype Cycle
Summary Adaptive Biotechnologies Corporation maintains a Hold rating as MRD segment momentum is offset by competitive and valuation concerns. ADPT's Q3 top-line strength was driven by a one-time Genentech payment; ex-Genentech, MRD revenue grew 52% Y/Y, showing underlying operational progress. MRD segment achieved standalone cash flow positivity, but consolidated profitability remains elusive without normalization; FY25 MRD guidance was raised. DLBCL market share defense and workflow integration are critical as competition intensifies, making 2026 a pivotal "prove it" year for ADPT. Read the full article on Seeking AlphaAnlatı Güncellemesi • Dec 15
ADPT: MRD Leadership Will Drive Long-Term Cash Flow Upside
Analysts have raised their fair value estimate for Adaptive Biotechnologies from approximately $15 to $21 per share. They cite higher long term profit margin expectations and confidence in the company’s leadership in minimal residual disease cancer testing, even with moderating revenue growth assumptions and a higher discount rate.Anlatı Güncellemesi • Nov 30
ADPT: Future Revenue Will Be Sustained By Leadership In Cancer Testing
Analysts have raised their fair value estimate for Adaptive Biotechnologies to $19.57 from $19.14. They cite increased confidence in the company's sustained revenue growth and leadership position in cancer testing.Anlatı Güncellemesi • Nov 16
ADPT: Future Revenue Will Be Driven By Market Expansion In Blood Cancer Testing
Analysts have raised their price target for Adaptive Biotechnologies by $2.00 to $19.14, citing the company's leadership in minimal residual disease testing, as well as expectations for sustained revenue growth and improved margins. Analyst Commentary Recent analyst discussions reveal diverse perspectives on Adaptive Biotechnologies' position in the market and future prospects.Anlatı Güncellemesi • Nov 01
ADPT: Leadership In Cancer Testing Will Drive Market Expansion And Execution Risks
Analysts have increased their price target for Adaptive Biotechnologies from $16.00 to $17.14 per share. They cite continuing leadership in cancer testing and expectations for robust revenue growth, driven by market expansion and operational improvements.Anlatı Güncellemesi • Oct 18
EMR Integration And Partnerships Will Reshape Clinical Diagnostics
Analysts have raised their price target for Adaptive Biotechnologies from $14.86 to $16.00. They cite the company’s strong positioning in cancer testing and sustained revenue growth potential.Analiz Makalesi • Oct 16
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 31% Jump Shows Its Popularity With Investors
Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have continued their recent momentum with a 31% gain in the...Anlatı Güncellemesi • Oct 04
EMR Integration And Partnerships Will Reshape Clinical Diagnostics
Analysts have increased their price target for Adaptive Biotechnologies from $14 to approximately $14.86 per share. They cite ongoing revenue growth momentum and strengthening leadership in the cancer diagnostics market as key drivers of the upward revision.Analiz Makalesi • Sep 24
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Aug 29
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 28% Share Price Bounce
Despite an already strong run, Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have been powering on, with...Anlatı Güncellemesi • Aug 07
EMR Integration And Partnerships Will Reshape Clinical Diagnostics
Despite a modest decline in consensus revenue growth forecasts and a slight increase in the discount rate, the consensus analyst price target for Adaptive Biotechnologies has been raised from $11.86 to $13.29. What's in the News Raised full year 2025 MRD business revenue guidance to $190–200 million from the prior $180–190 million range; no revenue guidance for Immune Medicine.Analiz Makalesi • May 31
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 29% Higher
Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shareholders would be excited to see that the share price has had...Analiz Makalesi • May 07
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analiz Makalesi • Apr 10
Why Investors Shouldn't Be Surprised By Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 26% Share Price Surge
The Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) share price has done very well over the last month, posting an...
Yeni Anlatı • Mar 25
ClonoSEQ And NovaSeq X Will Transform Clinical Testing Pipelines
Strategic partnerships and initiatives to raise test prices and efficiency are expected to drive substantial revenue and margin growth.Analiz Makalesi • Feb 14
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 40% Higher
Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have continued their recent momentum with a 40% gain in the...Seeking Alpha • Nov 26
Adaptive Biotechnologies: Making Some Progress
Summary Adaptive Biotechnologies posted strong Q3 results, beating expectations and reducing losses, while management has done a good job of reducing quarterly cash burn rates. The company's MRD segment, driven by clonoSEQ, continues to show significant growth, and the company's balance sheet remains strong. An updated analysis around Adaptive Biotechnologies follows in the paragraphs below. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 26
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce
Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have had a really impressive month, gaining 25% after a...Analiz Makalesi • Nov 01
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Oct 05
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher
Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have continued their recent momentum with a 27% gain in the...Analiz Makalesi • Jul 12
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk
With a median price-to-sales (or "P/S") ratio of close to 3.3x in the Life Sciences industry in the United States, you...Analiz Makalesi • May 08
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • Apr 03
It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
To the annoyance of some shareholders, Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares are down a...Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: ADPT şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.
Büyüyen Temettü: ADPT şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.
Piyasaya Karşı Temettü Getirisi
| Adaptive Biotechnologies Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (ADPT) | n/a |
| Pazarın Alt %25'i (US) | 1.4% |
| Pazarın En İyi %25'i (US) | 4.3% |
| Sektör Ortalaması (Life Sciences) | 0.7% |
| Analist tahmini (ADPT) (3 yıla kadar) | 0% |
Önemli Temettü: ADPT şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.
Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ADPT şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: ADPT şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: ADPT herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.
Güçlü temettü ödeyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/20 19:31 |
| Gün Sonu Hisse Fiyatı | 2026/05/20 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Adaptive Biotechnologies Corporation 13 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Derik de Bruin | BofA Global Research |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |